Serum Soluble VCAM-1, IL-8, and IL-1β as Inflammatory Biomarkers in Coronary Atherosclerosis A Case–Control Study
Abstract
Background: Coronary atherosclerosis is increasingly recognized as a chronic inflammatory disease of
the arterial wall; however, the simultaneous contribution of the endothelial adhesion molecule soluble
VCAM-1 (sVCAM-1) and the upstream pro-inflammatory cytokines IL-8 and IL-1β to disease
discrimination in Middle Eastern populations remains under-investigated. This study aimed to examine
the correlation of these specific immunological biomarkers with clinical metabolic profiles and
conventional inflammatory markers (such as hs-CRP and leukocyte counts) to evaluate their simultaneous
contribution to disease discrimination and to determine their combined clinical utility in reflecting the
atherosclerotic burden within a Middle Eastern population.
Methods: a case–control study enrolled 150 participants 100 patients with angiographically confirmed
coronary atherosclerosis and age-matched healthy controls in whom demographic, clinical, and metabolic
profiles were recorded and serum sVCAM-1, IL-8, and IL-1β were quantified by enzyme-linked
immunosorbent assay alongside hs-CRP, total leukocyte count, and neutrophil count.
Results: Atherosclerosis cases exhibited markedly elevated with significant difference sVCAM-1 , IL-8,
and IL-1β compared with controls (all p < 0.001), and were also older, more frequently male, hypertensive,
smokers, and dyslipidemic, with higher hs-CRP and leukocyte counts.
Conclusions: Collectively, these findings indicate that sVCAM-1, IL-8, and IL-1β are substantially
elevated in coronary atherosclerosis and meaningfully enhance inflammatory characterization beyond
conventional cardiovascular risk factors and hs-CRP alone, supporting their combined clinical utility as
candidate biomarkers of atherosclerotic burden.